1
|
Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care. Eur Psychiatry 2020; 23:561-6. [PMID: 18374544 DOI: 10.1016/j.eurpsy.2008.01.1421] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/12/2007] [Revised: 01/28/2008] [Accepted: 01/28/2008] [Indexed: 11/23/2022] Open
Abstract
AbstractBackgroundThis is a secondary analysis of clinical trial data collected in 12 European countries. We examined changes in weight and weight-related quality of life among community patients with schizophrenia treated with aripiprazole (ARI) versus standard of care (SOC), consisting of other marketed atypical antipsychotics (olanzapine, quetiapine, and risperidone).MethodFive-hundred and fifty-five patients whose clinical symptoms were not optimally controlled and/or experienced tolerability problems with current medication were randomized to ARI (10–30 mg/day) or SOC. Weight and weight-related quality of life (using the IWQOL-Lite) were assessed at baseline, and weeks 8, 18 and 26. Random regression analysis across all time points using all available data was used to compare groups on changes in weight and IWQOL-Lite. Meaningful change from baseline was also assessed.ResultsParticipants were 59.7% male, with a mean age of 38.5 years (SD 10.9) and mean baseline body mass index of 27.2 (SD 5.1). ARI participants lost an average of 1.7% of baseline weight in comparison to a gain of 2.1% by SOC participants (p < 0.0001) at 26 weeks. ARI participants experienced significantly greater increases in physical function, self-esteem, sexual life, and IWQOL-Lite total score. At 26 weeks, 20.7% of ARI participants experienced meaningful improvements in IWQOL-Lite score, versus 13.5% of SOC participants. A clinically meaningful change in weight was also associated with a meaningful change in quality of life (p < 0.001). A potential limitation of this study was its funding by a pharmaceutical company.ConclusionsCompared to standard of care, patients with schizophrenia treated with aripiprazole experienced decreased weight and improved weight-related quality of life over 26 weeks. These changes were both statistically and clinically significant.
Collapse
|
2
|
Painold A, Mörkl S, Kashofer K, Halwachs B, Dalkner N, Bengesser S, Birner A, Fellendorf F, Platzer M, Queissner R, Schütze G, Schwarz MJ, Moll N, Holzer P, Holl AK, Kapfhammer H, Gorkiewicz G, Reininghaus EZ. A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode. Bipolar Disord 2019; 21:40-49. [PMID: 30051546 PMCID: PMC6585963 DOI: 10.1111/bdi.12682] [Citation(s) in RCA: 118] [Impact Index Per Article: 23.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
OBJECTIVES There is evidence that the gut microbiota plays a major role in the pathogenesis of diseases of the central nervous system through the gut-brain axis. The aim of the present study was to analyze gut microbiota composition in bipolar disorder (BD) and its relation to inflammation, serum lipids, oxidative stress, tryptophan (TRP)/kynurenine (KYN) levels, anthropometric measurements and parameters of metabolic syndrome. Further, microbial community differences of individuals with BD compared with healthy controls (HC) were explored. METHODS In this cross-sectional study, we performed 16S rRNA gene sequencing of stool samples from 32 BD individuals and 10 HC. Laboratory parameters included inflammatory markers, serum lipids, KYN, oxidative stress and anthropometric measures. Microbial community analysis and correlation to clinical parameters was performed with QIIME, differential abundance analysis of taxa encompassed linear discriminant analysis effect size (LEfSe). RESULTS We found a negative correlation between microbial alpha-diversity and illness duration in BD (R = -0.408, P = 0.021). Furthermore, we identified bacterial clades associated with inflammatory status, serum lipids, TRP, depressive symptoms, oxidative stress, anthropometrics and metabolic syndrome in individuals with BD. LEfSe identified the phylum Actinobacteria (LDA= 4.82, P = 0.007) and the class Coriobacteria (LDA= 4.75, P = 0.010) as significantly more abundant in BD when compared with HC, and Ruminococcaceae (LDA= 4.59, P = 0.018) and Faecalibacterium (LDA= 4.09, P = 0.039) as more abundant in HC when compared with BD. CONCLUSIONS The present findings suggest that causes and/or consequences of BD may also lie outside the brain. Exploratory research of the gut microbiota in affective disorders like BD may identify previously unknown underlying causes, and offer new research and therapeutic approaches to mood disorders.
Collapse
Affiliation(s)
- Annamaria Painold
- Department of Psychiatry and Psychotherapeutic MedicineMedical University of GrazGrazAustria
| | - Sabrina Mörkl
- Department of Psychiatry and Psychotherapeutic MedicineMedical University of GrazGrazAustria
| | - Karl Kashofer
- Institute of PathologyMedical University of GrazGrazAustria
| | | | - Nina Dalkner
- Department of Psychiatry and Psychotherapeutic MedicineMedical University of GrazGrazAustria
| | - Susanne Bengesser
- Department of Psychiatry and Psychotherapeutic MedicineMedical University of GrazGrazAustria
| | - Armin Birner
- Department of Psychiatry and Psychotherapeutic MedicineMedical University of GrazGrazAustria
| | - Frederike Fellendorf
- Department of Psychiatry and Psychotherapeutic MedicineMedical University of GrazGrazAustria
| | - Martina Platzer
- Department of Psychiatry and Psychotherapeutic MedicineMedical University of GrazGrazAustria
| | - Robert Queissner
- Department of Psychiatry and Psychotherapeutic MedicineMedical University of GrazGrazAustria
| | - Gregor Schütze
- Institute of Laboratory MedicineMedical Center of Munich University (LMU)MunichGermany
| | - Markus J. Schwarz
- Institute of Laboratory MedicineMedical Center of Munich University (LMU)MunichGermany
| | - Natalie Moll
- Institute of Laboratory MedicineMedical Center of Munich University (LMU)MunichGermany
| | - Peter Holzer
- Institute of Experimental and Clinical PharmacologyMedical University of GrazGrazAustria
| | - Anna K. Holl
- Department of Psychiatry and Psychotherapeutic MedicineMedical University of GrazGrazAustria
| | - Hans‐Peter Kapfhammer
- Department of Psychiatry and Psychotherapeutic MedicineMedical University of GrazGrazAustria
| | | | - Eva Z. Reininghaus
- Department of Psychiatry and Psychotherapeutic MedicineMedical University of GrazGrazAustria
| |
Collapse
|
3
|
Wharton S, Raiber L, Serodio KJ, Lee J, Christensen RA. Medications that cause weight gain and alternatives in Canada: a narrative review. Diabetes Metab Syndr Obes 2018; 11:427-438. [PMID: 30174450 PMCID: PMC6109660 DOI: 10.2147/dmso.s171365] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND The cause of the obesity epidemic is multifactorial, but may, in part, be related to medication-induced weight gain. While clinicians may strive to do their best to select pharmacotherapy(ies) that has the least negative impact on weight, the literature regarding the weight effects of medication is often limited and devoid of alternative therapies. RESULTS Antipsychotics, antidepressants, antihyperglycemics, antihypertensives and corticosteroids all contain medications that were associated with significant weight gain. However, there are several medication alternatives within the majority of these classes associated with weight neutral or even weight loss effects. Further, while not all of the classes of medication examined in this review have weight-favorable alternatives, there exist many other tools to mitigate weight gain associated with medication use, such as changes in dosing, medication delivery or the use of adjunctive therapies. CONCLUSION Medication-induced weight gain can be frustrating for both the patient and the clinician. As the use of pharmaceuticals continues to increase, it is pertinent for clinicians to consider the weight effects of medications prior to prescribing or in the course of treatment. In the case where it is not feasible to make changes to medication, adjunctive therapies should be considered.
Collapse
Affiliation(s)
- Sean Wharton
- The Wharton Medical Clinic, Toronto, Canada,
- School of Kinesiology and Health Science, York University, Toronto, Canada
| | | | | | - Jasmine Lee
- The Wharton Medical Clinic, Toronto, Canada,
| | | |
Collapse
|
4
|
Maternal smoking and low family income during pregnancy as predictors of the relationship between depression and adiposity in young adults. J Dev Orig Health Dis 2018; 9:552-560. [PMID: 30111386 DOI: 10.1017/s2040174418000533] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
There is an increasing incidence of overweight/obesity and mental health disorders in young adults and the two conditions often coexist. We aimed to investigate the influence of antenatal and postnatal factors that may underlie this association with a focus on maternal prenatal smoking, socio-economic status and gender. Data from the Western Australian Pregnancy Cohort (Raine) Study (women enrolled 1989-1991) including 1056 offspring aged 20 years (cohort recalled 2010-2012) were analyzed (2015-2016) using multivariable models for associations between offspring depression scores (DASS-21 Depression-scale) and body mass index (BMI), adjusting for pregnancy and early life factors and offspring behaviours. There was a significant positive relationship between offspring depression-score and BMI independent of gender and other psychosocial covariates. There was a significant interaction between maternal prenatal smoking and depression-score (interaction coefficient=0.096; 95% CI: 0.006, 0.19, P=0.037), indicating the relationship between depression-score and BMI differed according to maternal prenatal smoking status. In offspring of maternal prenatal smokers, a positive association between BMI and depression-score (coefficient=0.133; 95% CI: 0.05, 0.21, P=0.001) equated to 1.1 kg/m2 increase in BMI for every 1standard deviation (8 units) increase in depression-score. Substituting low family income during pregnancy for maternal prenatal smoking in the interaction (interaction coefficient=0.091; 95% CI: 0.01, 0.17, P=0.027) showed a positive association between BMI and depression score only among offspring of mothers with a low family income during pregnancy (coefficient=0.118; 95% CI: 0.06, 0.18, P<0.001). There were no significant effects of gender on these associations. Whilst further studies are needed to determine whether these associations are supported in other populations, they suggest potentially important maternal behavioural and socio-economic factors that identify individuals vulnerable to the coexistence of obesity and depression in early adulthood.
Collapse
|
5
|
Chaturvedi HK, Bajpai RC, Tiwari P. Association of religion and cultural tradition with alcohol use among some tribal communities of Arunachal Pradesh, India. J Ethn Subst Abuse 2017; 18:296-308. [DOI: 10.1080/15332640.2017.1355766] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
| | - Ram C. Bajpai
- Indian Council of Medical Research, New Delhi, India
| | - Preeti Tiwari
- Indian Council of Medical Research, New Delhi, India
| |
Collapse
|
6
|
Dalkner N, Platzer M, Bengesser SA, Birner A, Fellendorf FT, Queissner R, Painold A, Mangge H, Fuchs D, Reininghaus B, Kapfhammer HP, Holasek SJ, Reininghaus EZ. The role of tryptophan metabolism and food craving in the relationship between obesity and bipolar disorder. Clin Nutr 2017; 37:1744-1751. [PMID: 28712531 DOI: 10.1016/j.clnu.2017.06.024] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2017] [Revised: 06/22/2017] [Accepted: 06/25/2017] [Indexed: 10/19/2022]
Abstract
BACKGROUND & AIMS Individuals with bipolar disorder (BD) have a significantly increased risk of obesity-related conditions. The imbalance between food intake and energy expenditure is assumed to be a major risk factor for obesity in BD. This study analyzed food craving in relation to anthropometric, metabolic, and neurobiological parameters in a well-characterized cohort of euthymic individuals with BD. METHODS One-hundred-thirty-five patients completed the Food-Craving Inventory assessing four categories of food craving (fat, fast-food, sweets and carbohydrate craving). Additionally, clinical, metabolic and anthropometric parameters were assessed. RESULTS Higher levels of fat craving were observed in males, versus females, with BD. High levels of carbohydrate craving positively correlated with kynurenine and the kynurenine-to-tryptophan ratio. Higher serum nitrite and neopterin levels were related to fat craving. Parameters of fat metabolism (triglycerides, high-density lipoprotein) were associated with fat and fast-food craving. Anthropometric measures of obesity (e.g. body mass index, waist-to-hip-ratio) were not related to food craving. CONCLUSIONS Overweight/obese individuals with BD show an increased driving of tryptophan down the kynurenine pathways, as indicated by an increase in the serum kynurenine-to-tryptophan ratio. The driving of tryptophan down the kynurenine pathway is mediated by immune-inflammatory activity and stress. The correlation of increased kynurenine with food craving, especially carbohydrate craving, probably indicates a regulatory deficit in the maintenance of chronic inflammatory processes in obesity and BD. Food craving seems to be of clinical importance in the treatment of metabolic disturbances in BD, although not associated with anthropometric measures of obesity. Rather, food craving correlates with blood metabolic parameters and an increased activation of the kynurenine pathway, both of which are linked to higher affective symptomatology and the development of cardiovascular diseases.
Collapse
Affiliation(s)
- N Dalkner
- Department of Psychiatry, Medical University Graz, Austria
| | - M Platzer
- Department of Psychiatry, Medical University Graz, Austria.
| | - S A Bengesser
- Department of Psychiatry, Medical University Graz, Austria
| | - A Birner
- Department of Psychiatry, Medical University Graz, Austria
| | - F T Fellendorf
- Department of Psychiatry, Medical University Graz, Austria
| | - R Queissner
- Department of Psychiatry, Medical University Graz, Austria
| | - A Painold
- Department of Psychiatry, Medical University Graz, Austria
| | - H Mangge
- Research Unit on Lifestyle and Inflammation-associated Risk Biomarkers, Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University Graz, Austria
| | - D Fuchs
- Division of Biological Chemistry, Biocenter, Medical University of Innsbruck, Austria
| | - B Reininghaus
- Therapiezentrum Justuspark, Versicherungsanstalt öffentlich Bediensteter, Bad Hall, Austria
| | - H P Kapfhammer
- Department of Psychiatry, Medical University Graz, Austria
| | - S J Holasek
- Department of Pathophysiology and Immunology, Medical University Graz, Austria
| | | |
Collapse
|
7
|
Stanford FC, Alfaris N, Gomez G, Ricks ET, Shukla AP, Corey KE, Pratt JS, Pomp A, Rubino F, Aronne LJ. The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: A multi-center study. Surg Obes Relat Dis 2016; 13:491-500. [PMID: 27986587 DOI: 10.1016/j.soard.2016.10.018] [Citation(s) in RCA: 115] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2016] [Revised: 10/13/2016] [Accepted: 10/23/2016] [Indexed: 02/07/2023]
Abstract
BACKGROUND Patients who undergo bariatric surgery often have inadequate weight loss or weight regain. OBJECTIVES We sought to discern the utility of weight loss pharmacotherapy as an adjunct to bariatric surgery in patients with inadequate weight loss or weight regain. SETTING Two academic medical centers. METHODS We completed a retrospective study to identify patients who had undergone bariatric surgery in the form of a Roux-en-Y gastric bypass (RYGB) or a sleeve gastrectomy from 2000-2014. From this cohort, we identified patients who were placed on weight loss pharmacotherapy postoperatively for inadequate weight loss or weight regain. We extracted key demographic data, medical history, and examined weight loss in response to surgery and after the initiation of weight loss pharmacotherapy. RESULTS A total of 319 patients (RYGB = 258; sleeve gastrectomy = 61) met inclusion criteria for analysis. More than half (54%; n = 172) of all study patients lost≥5% (7.2 to 195.2 lbs) of their total weight with medications after surgery. There were several high responders with 30.3% of patients (n = 96) and 15% (n = 49) losing≥10% (16.7 to 195.2 lbs) and≥15% (25 to 195.2 lbs) of their total weight, respectively, Topiramate was the only medication that demonstrated a statistically significant response for weight loss with patients being twice as likely to lose at least 10% of their weight when placed on this medication (odds ratio = 1.9; P = .018). Regardless of the postoperative body mass index, patients who underwent RYGB were significantly more likely to lose≥5% of their total weight with the aid of weight loss medications. CONCLUSIONS Weight loss pharmacotherapy serves as a useful adjunct to bariatric surgery in patients with inadequate weight loss or weight regain.
Collapse
Affiliation(s)
- Fatima Cody Stanford
- MGH Weight Center, Gastrointestinal Unit-Department of Medicine, Massachusetts General Hospital, Boston, MA; Endocrine Unit, Department of Pediatrics, Massachusetts General Hospital, Boston, MA; Harvard Medical School, Boston, MA.
| | - Nasreen Alfaris
- MGH Weight Center, Gastrointestinal Unit-Department of Medicine, Massachusetts General Hospital, Boston, MA; Harvard Medical School, Boston, MA; Obesity, Metabolism and Nutrition Institute, Massachusetts General Hospital, Boston, MA
| | - Gricelda Gomez
- Harvard Medical School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA
| | - Elizabeth T Ricks
- Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Weill Cornell Medical College, New York, NY; Institute of Human Nutrition, Columbia University, New York, NY; Texas Tech University- Paul L. Foster School of Medicine, El Paso, TX
| | - Alpana P Shukla
- Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Weill Cornell Medical College, New York, NY
| | - Kathleen E Corey
- Harvard Medical School, Boston, MA; Gastrointestinal Unit-Department of Medicine, Massachusetts General Hospital, Boston, MA
| | - Janey S Pratt
- Harvard Medical School, Boston, MA; Department of Surgery, Massachusetts General Hospital, Boston, MA
| | - Alfons Pomp
- Department of GI Metabolic and Bariatric Surgery, Weill Cornell Medical College, New York, NY
| | - Francesco Rubino
- Department of Metabolic and Bariatric Surgery, Kings College London and Kings College Hospital, London, UK
| | - Louis J Aronne
- Institute of Human Nutrition, Columbia University, New York, NY
| |
Collapse
|
8
|
Jonikas JA, Cook JA, Razzano LA, Steigman PJ, Hamilton MM, Swarbrick MA, Santos A. Associations Between Gender and Obesity Among Adults with Mental Illnesses in a Community Health Screening Study. Community Ment Health J 2016; 52:406-15. [PMID: 26711093 PMCID: PMC4833836 DOI: 10.1007/s10597-015-9965-2] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/28/2015] [Accepted: 11/08/2015] [Indexed: 12/20/2022]
Abstract
The prevalence of obesity and its associations with gender, clinical factors, and medical co-morbidities were examined among 457 adults attending public mental health programs in 4 U.S. states. BMI was measured directly and other information was gathered by interview. Over half (59%, n = 270) were obese including 18% (n = 83) who were morbidly obese. In hierarchical ordinary least squares regression analysis controlling for demographic, psychiatric, medical, smoking, and health insurance statuses, women were significantly more likely to be obese than men. Obesity also was more likely among those who were younger and not high school graduates, those with diabetes or hypertension, and those who did not smoke tobacco. Interaction effects were found between gender and diabetes, hypertension, tobacco smoking, education, race, and age. The high prevalence of obesity among women, coupled with interactions between gender and other factors, suggest that targeted approaches are needed to promote optimal physical health in this population.
Collapse
Affiliation(s)
- Jessica A Jonikas
- Department of Psychiatry, Center on Mental Health Services Research and Policy, University of Illinois at Chicago, 1601 West Taylor Street, M/C 912, Chicago, IL, 60612, USA.
| | - Judith A Cook
- Department of Psychiatry, Center on Mental Health Services Research and Policy, University of Illinois at Chicago, 1601 West Taylor Street, M/C 912, Chicago, IL, 60612, USA
| | - Lisa A Razzano
- Department of Psychiatry, Center on Mental Health Services Research and Policy, University of Illinois at Chicago, 1601 West Taylor Street, M/C 912, Chicago, IL, 60612, USA
| | - Pamela J Steigman
- Department of Psychiatry, Center on Mental Health Services Research and Policy, University of Illinois at Chicago, 1601 West Taylor Street, M/C 912, Chicago, IL, 60612, USA
| | - Marie M Hamilton
- Department of Psychiatry, Center on Mental Health Services Research and Policy, University of Illinois at Chicago, 1601 West Taylor Street, M/C 912, Chicago, IL, 60612, USA
| | - Margaret A Swarbrick
- Collaborative Support Programs of New Jersey, Department of Psychiatric Rehabilitation and Counseling Professions, Rutgers, The State University of New Jersey, 8 Spring Street, Freehold, NJ, 07728, USA
| | - Alberto Santos
- Department of Psychiatry and Health Behavior, Georgia Regents University, 1120 15th Street, Augusta, GA, 30912, USA
| |
Collapse
|
9
|
Saberi Zafarghandi MB, Jadidi M, Khalili N. Iran's Activities on Prevention, Treatment and Harm Reduction of Drug Abuse. INTERNATIONAL JOURNAL OF HIGH RISK BEHAVIORS & ADDICTION 2015; 4:e22863. [PMID: 26870709 PMCID: PMC4744908 DOI: 10.5812/ijhrba.22863] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 08/17/2014] [Revised: 03/28/2015] [Accepted: 04/28/2015] [Indexed: 06/05/2023]
Abstract
CONTEXT In the present review study, authors investigated Iran's activities regarding prevention, abuse and harm reduction of drugs nationwide. The issue appears to be important in order to show the trend of activities in the country. EVIDENCE ACQUISITION In this report, authors gathered data from different Farsi/English peer review journals issued both in printed and online versions. These journals have been indexed in PubMed, ISI, ISC, SID, Magiran, UN, etc. These are among the most referred and cited databases. RESULTS Summarizing the data led to three distinguished sections: 1) drug supply reduction activities; 2) drug demand reduction activities; 3) harm reduction activities. CONCLUSIONS As the results showed, the trend of activities was encouraging and some additional activities could be included to future programs relying on early-onset preventions.
Collapse
Affiliation(s)
- Mohammad Bagher Saberi Zafarghandi
- Department of Addiction, Mental Health Research Center, School of Behavioral Sciences and Mental Health, Tehran Institute of Psychiatry, Iran University of Medical Sciences, Tehran, IR Iran
| | - Mohsen Jadidi
- Department of Psychology, Bandargaz Branch, Islamic Azad University, Bandargaz, IR Iran
| | - Narjes Khalili
- Drug Control Headquarters, Presidency of Islamic Republic of Iran, Tehran, IR Iran
| |
Collapse
|
10
|
Jensen-Otsu E, Austin GL. Antidepressant Use is Associated with Increased Energy Intake and Similar Levels of Physical Activity. Nutrients 2015; 7:9662-71. [PMID: 26610562 PMCID: PMC4663617 DOI: 10.3390/nu7115489] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2015] [Revised: 10/22/2015] [Accepted: 10/22/2015] [Indexed: 11/16/2022] Open
Abstract
Antidepressants have been associated with weight gain, but the causes are unclear. The aims of this study were to assess the association of antidepressant use with energy intake, macronutrient diet composition, and physical activity. We used data on medication use, energy intake, diet composition, and physical activity for 3073 eligible adults from the 2005–2006 National Health and Nutrition Examination Survey (NHANES). Potential confounding variables, including depression symptoms, were included in the models assessing energy intake, physical activity, and sedentary behavior. Antidepressant users reported consuming an additional (mean ± S.E.) 215 ± 73 kcal/day compared to non-users (p = 0.01). There were no differences in percent calories from sugar, fat, or alcohol between the two groups. Antidepressant users had similar frequencies of walking or biking, engaging in muscle-strengthening activities, and engaging in moderate or vigorous physical activity. Antidepressant users were more likely to use a computer for ≥2 h/day (OR 1.77; 95% CI: 1.09–2.90), but TV watching was similar between the two groups. These results suggest increased energy intake and sedentary behavior may contribute to weight gain associated with antidepressant use. Focusing on limiting food intake and sedentary behaviors may be important in mitigating the weight gain associated with antidepressant use.
Collapse
Affiliation(s)
- Elsbeth Jensen-Otsu
- Division of Gastroenterology, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195, USA.
| | - Gregory L Austin
- Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Campus, 12631 E. 17th Ave., Room 7619, Aurora, CO 80045, USA.
| |
Collapse
|
11
|
de Wit LM, van Straten A, Lamers F, Cuijpers P, Penninx BWJH. Depressive and anxiety disorders: Associated with losing or gaining weight over 2 years? Psychiatry Res 2015; 227:230-7. [PMID: 25895491 DOI: 10.1016/j.psychres.2015.02.025] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/11/2014] [Revised: 01/19/2015] [Accepted: 02/01/2015] [Indexed: 01/15/2023]
Abstract
This longitudinal study examines to what extent different depressive and anxiety disorders and clinical characteristics are associated with subsequent weight change, while controlling for baseline weight, sociodemographics, health status, psychotropic medication use and (un)healthy lifestyle factors. Data are from a sample of 2447 respondents aged 18-65 years of the Netherlands Study of Depression and Anxiety (NESDA). Baseline depressive disorders and anxiety disorders were determined with the Composite International Diagnostic Interview (CIDI). Weight at baseline and after 2 years was measured and analyzed as continuous change score (mean change in weight 1kg) and in categories of significant weight loss (<1S.D. weight change equaling <4kg), weight maintenance and weight gain (>1S.D., >6kg). After full adjustment for covariates baseline comorbid anxiety and depressive disorder and baseline Major Depressive Disorder (MDD) were associated with significant 2-year weight gain. Both current and remitted MDD at baseline and a baseline dysthymia, but none of the anxiety disorders, were associated with significant weight loss. This longitudinal study confirms a U-curved link between depression and weight change over 2 years. Furthermore, a dose-response effect of depression severity on 2-year weight gain was found.
Collapse
Affiliation(s)
- Leonore M de Wit
- Department of Clinical Psychology and EMGO Institute, VU University Amsterdam, van der Boechorststraat 1, 1081 BT, Amsterdam, The Netherlands.
| | - Annemieke van Straten
- Department of Clinical Psychology and EMGO Institute, VU University Amsterdam, van der Boechorststraat 1, 1081 BT, Amsterdam, The Netherlands
| | - Femke Lamers
- Department of Psychiatry and EMGO Institute, VU University Medical Center, Amsterdam, The Netherlands
| | - Pim Cuijpers
- Department of Clinical Psychology and EMGO Institute, VU University Amsterdam, van der Boechorststraat 1, 1081 BT, Amsterdam, The Netherlands
| | - Brenda W J H Penninx
- Department of Psychiatry and EMGO Institute, VU University Medical Center, Amsterdam, The Netherlands; Department of Psychiatry, Leiden University Medical Center, Leiden, The Netherlands; Department of Psychiatry, University Medical Center Groningen, Groningen, The Netherlands
| |
Collapse
|
12
|
Milano W, De Rosa M, Milano L, Capasso A. Antipsychotic drugs opposite to metabolic risk: neurotransmitters, neurohormonal and pharmacogenetic mechanisms underlying with weight gain and metabolic syndrome. Open Neurol J 2013; 7:23-31. [PMID: 23894259 PMCID: PMC3722531 DOI: 10.2174/1874205x01307010023] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2013] [Revised: 03/15/2013] [Accepted: 03/20/2013] [Indexed: 12/16/2022] Open
Abstract
Important sources of metabolic diseases such as obesity and metabolic syndrome are significantly more prevalent in patients treated with antipsychotic drugs than the general population and they not only reduce the quality of life but also significantly reduce the life expectancy, being important risk factors for cardiovascular disease. The pathogenic mechanisms underlying these events are not entirely clear they are complex and multi-determined or not tied to a single defining event. In this review we examine the literature on the interactions of antipsychotic drugs with neurotransmitters in the brain, with pharmacogenetics hormones and peripheral mechanisms that may induce, albeit in different ways between different molecules, not only weight gain but also 'onset of major diseases such as diabetes, dyslipidemia and hypertension that are the basis of the metabolic syndrome. Today, the possible metabolic changes induced by various antipsychotic drugs and their major physical health consequences, are among the major concerns of clinicians and it is therefore necessary to monitor the main metabolic parameters to prevent or minimize any of these patients as well as the metabolism events associated with the use of antipsychotic drugs.
Collapse
Affiliation(s)
- Walter Milano
- Mental Health Unit- District 24 – ASL Napoli 1 Center, Italy
| | - Michele De Rosa
- Mental Health Unit- District 24 – ASL Napoli 1 Center, Italy
| | - Luca Milano
- Mental Health Unit- District 24 – ASL Napoli 1 Center, Italy
| | - Anna Capasso
- Department of Pharmacy, University of Salerno, Italy
| |
Collapse
|
13
|
Chaturvedi HK, Mahanta J, Bajpai RC, Pandey A. Correlates of opium use: retrospective analysis of a survey of tribal communities in Arunachal Pradesh, India. BMC Public Health 2013; 13:325. [PMID: 23575143 PMCID: PMC3626656 DOI: 10.1186/1471-2458-13-325] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2012] [Accepted: 04/04/2013] [Indexed: 12/03/2022] Open
Abstract
Background Household survey data of Changlang district, Arunachal Pradesh, were used in the present study to assess the prevalence of opium use among different tribes, and to examine the association between sociodemographic factors and opium use. Methods A sample of 3421 individuals (1795 men and 1626 women) aged 15 years and older was analyzed using a multivariate logistic regression model to determine factors associated with opium use. Sociodemographic information such as age, education, occupation, religion, ethnicity and marital status were included in the analysis. Results The prevalence of opium use was significantly higher (10.6%) among men than among women (2.1%). It varied according to age, educational level, occupation, marital status and religion of the respondents. In both sexes, opium use was significantly higher among Singpho and Khamti tribes compared with other tribes. Multivariate logistic regression indicated that opium use was significantly associated with age, occupation, ethnicity, religion and marital status of the respondents of both sexes. Multivariate rate ratios (MRR) for opium use were significantly higher (4–6 times) among older age groups (≥35 years) and male respondents. In males, the MRR was also significantly higher in respondents of Buddhist and Indigenous religion, while in females, the MRR was significantly higher in Buddhists. Most of the female opium users had taken opium for more than 5 years and were introduced to it by their husbands after marriage. Use of other substances among opium users comprised mainly tobacco (76%) and alcohol (44%). Conclusions The study reveals the sociodemographic factors, such as age, sex, ethnicity, religion and occupation, which are associated with opium use. Such information is useful for institution of intervention measures to reduce opium use.
Collapse
|
14
|
Feng XM, Xiong J, Qin H, Liu W, Chen RN, Shang W, Ning R, Hu G, Yang J. Fluoxetine induces hepatic lipid accumulation via both promotion of the SREBP1c-related lipogenesis and reduction of lipolysis in primary mouse hepatocytes. CNS Neurosci Ther 2012; 18:974-80. [PMID: 23137031 DOI: 10.1111/cns.12014] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2012] [Revised: 08/28/2012] [Accepted: 08/30/2012] [Indexed: 11/28/2022] Open
Abstract
AIMS In this study, we investigated the peripheral mechanisms underlying the metabolic side effects of fluoxetine (FLX) by focusing on hepatic lipid metabolism. METHODS Primary mouse hepatocytes were prepared from male mice by the two-step perfusion method. The lipid accumulation in primary mouse hepatocytes was analyzed via neutral oil staining. And the lipid metabolism enzymes were determined with RT-PCR and Western blot. RESULTS Fluoxetine significantly induced the lipid accumulation in primary mouse hepatocytes. Moreover, FLX increased the acetyl-CoA carboxylase 1 (ACC1) and fatty acid synthase (FAS) expression, which are important enzymes in lipogenesis. Oppositely, Fluoxetine significantly decreased the carboxylesterase 3 (CES3) and carboxylesterase 1 (CES1) expression, which are related to lipolysis. Further study demonstrated FLX-activated SREBP1c, which is one of the most important transcription factors conducting coordinated transcriptional regulation of lipogenesis gene such as ACC1 and FAS. And the increase of lipogenesis gene (ACC1) was abolished by SB203580 but not by pyrrolidine dithiocarbamate (PDTC), suggesting through p38-MAPK pathway. CONCLUSION Fluoxetine induces hepatic lipid accumulation via both promotion of the SREBP1c-related lipogenesis and reduction of lipolysis in primary mouse hepatocytes.
Collapse
Affiliation(s)
- Xue-Min Feng
- Department of Pharmacology, Nanjing Medical University, Nanjing, China
| | | | | | | | | | | | | | | | | |
Collapse
|
15
|
|
16
|
Zhang Y, Dai G. Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China. Hum Psychopharmacol 2012; 27:605-14. [PMID: 24446539 DOI: 10.1002/hup.2270] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
BACKGROUND There are no direct comparisons of paliperidone extended-release (ER), aripiprazole and ziprasidone in efficacy and metabolic influence in patients with first-episode schizophrenia. OBJECTIVE The present study examined the efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone in patients with first-episode schizophrenia in China. METHODS Subjects were recruited from outpatient and 254 patients entered the trial. These patients received treatment randomly with paliperidone ER, aripiprazole and ziprasidone and were assessed at baseline, 13, 26 and 52 weeks, respectively with Positive and Negative Syndrome Scale (PANSS), 7-item Clinical Global Impressions-Severity (CGI-S), anthropometric (weight, body mass index and waist circumference) and metabolic (fasting blood glucose, HbA1c, cholesterol, high density lipoproteins (HDL), low density lipoproteins and triglycerides) measures. RESULTS A total of 203 patients completed the trial. Paliperidone group had significant greater reduction in PANSS than aripiprazole group and ziprasidone group from 13 weeks, although the a reduction in PANSS of each group was more than 20%. There was no difference in CGI-S among the three groups, and all three groups had a significant reduction from baseline in CGI-S. Aripiprazole group increased in weight and body mass index despite no statistical change in waist circumference. Other two groups showed no changes in anthropometric measure. At the end of the study, two glucose metabolic indices (fasting blood glucose and HbA1c) of aripiprazole group were significantly higher than that of baseline. In lipid metabolism, aripiprazole group reduced triglycerides significantly and had no changes in other indices. Paliperidone group reduced HDL and increased triglycerides despite no changes in glucose metabolism. Ziprasidone group also had no significant changes in glucose metabolism, but reduced cholesterol, low density lipoproteins and increased HDL. Furthermore, 22 subjects in three groups reached the diagnostic criteria of metabolic syndrome. CONCLUSIONS Paliperidone ER, aripiprazole and ziprasidone are effective in treating first-episode schizophrenia, and the ranking of efficacy from high to low is paliperidone ER > aripiprazole > ziprasidone. Paliperidone ER can impair lipid metabolism potentially but had no influence on glucose metabolism. Aripiprazole can damage glucose metabolism and has little influence on lipid metabolism. Ziprasidone is considered an atypical antipsychotic with no evidence of harm to glucose and lipid metabolism.
Collapse
Affiliation(s)
- Yinbo Zhang
- Chengdu Mental Health Center, Fourth People's Hospital, Chengdu, China.
| | | |
Collapse
|
17
|
Filia SL, Baker AL, Kulkarni J, Williams JM. Sequential behavioral treatment of smoking and weight control in bipolar disorder. Transl Behav Med 2012; 2:290-5. [PMID: 24073127 PMCID: PMC3717911 DOI: 10.1007/s13142-012-0111-1] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Abstract
People with severe mental illnesses like schizophrenia and bipolar disorder (BPAD) live significantly shorter lives than people in the general population and most commonly die of cardiovascular disease (CVD). CVD risk behaviors such as smoking are not routinely assessed or assertively treated among people with a severe mental illness. This article provides an illustrative case example of a woman with BPAD who is motivated to quit smoking, despite concerns about weight gain and relapse to depression. It outlines key considerations and describes the patient's experience of participating in a behavioral intervention focussing first on smoking, then diet and physical activity. Clinical challenges encountered during treatment are discussed in the context of relevant literature. These include motivational issues, relapse to depression, medication interactions, weight gain, addressing multiple health behavior change, focussing on a behavioral rather than cognitive approach, collaborating with other health care providers, and gender issues.
Collapse
Affiliation(s)
- Sacha L Filia
- />Monash Alfred Psychiatry Research Centre (MAPrc), Monash University, Level 1, Old Baker Building, The Alfred Hospital, PO Box 315, Prahran, VIC 3181 Australia
| | - Amanda L Baker
- />Centre for Brain and Mental Health Research (CBMHR), University of Newcastle, Newcastle, NSW Australia
| | - Jayashri Kulkarni
- />Monash Alfred Psychiatry Research Centre (MAPrc), Monash University, Level 1, Old Baker Building, The Alfred Hospital, PO Box 315, Prahran, VIC 3181 Australia
| | - Jill M Williams
- />Division of Addiction Psychiatry, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ USA
| |
Collapse
|
18
|
Alemany M. Do the interactions between glucocorticoids and sex hormones regulate the development of the metabolic syndrome? Front Endocrinol (Lausanne) 2012; 3:27. [PMID: 22649414 PMCID: PMC3355885 DOI: 10.3389/fendo.2012.00027] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/27/2011] [Accepted: 02/06/2012] [Indexed: 12/14/2022] Open
Abstract
The metabolic syndrome is basically a maturity-onset disease. Typically, its manifestations begin to flourish years after the initial dietary or environmental aggression began. Since most hormonal, metabolic, or defense responses are practically immediate, the procrastinated response do not seem justified. Only in childhood, the damages of the metabolic syndrome appear with minimal delay. Sex affects the incidence of the metabolic syndrome, but this is more an effect of timing than absolute gender differences, females holding better than males up to menopause, when the differences between sexes tend to disappear. The metabolic syndrome is related to an immune response, countered by a permanent increase in glucocorticoids, which keep the immune system at bay but also induce insulin resistance, alter the lipid metabolism, favor fat deposition, mobilize protein, and decrease androgen synthesis. Androgens limit the operation of glucocorticoids, which is also partly blocked by estrogens, since they decrease inflammation (which enhances glucocorticoid release). These facts suggest that the appearance of the metabolic syndrome symptoms depends on the strength (i.e., levels) of androgens and estrogens. The predominance of glucocorticoids and the full manifestation of the syndrome in men are favored by decreased androgen activity. Low androgens can be found in infancy, maturity, advanced age, or because of their inhibition by glucocorticoids (inflammation, stress, medical treatment). Estrogens decrease inflammation and reduce the glucocorticoid response. Low estrogen (infancy, menopause) again allow the predominance of glucocorticoids and the manifestation of the metabolic syndrome. It is postulated that the equilibrium between sex hormones and glucocorticoids may be a critical element in the timing of the manifestation of metabolic syndrome-related pathologies.
Collapse
Affiliation(s)
- Marià Alemany
- Faculty of Biology, Department of Nutrition and Food Science, University of Barcelona Barcelona, Spain.
| |
Collapse
|
19
|
Roose S, Deuschle M. Depression and cardiovascular disorders. HANDBOOK OF CLINICAL NEUROLOGY 2012; 106:541-556. [PMID: 22608643 DOI: 10.1016/b978-0-444-52002-9.00032-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Affiliation(s)
- Steven Roose
- Department of Psychiatry, Columbia University, New York, NY, USA
| | | |
Collapse
|
20
|
Abstract
Insomnia is a common, often chronic medical disorder with significant medical and socioeconomic repercussions. However, unlike other medical conditions, there is intense debate as to whether the long-term treatment of insomnia is clinically appropriate. The perceived deleterious side effect of sedative-hypnotic medications may result in patients remaining untreated or undertreated. This review proposes that a more subtle approach needs to be taken in the management of patients with chronic insomnia and that long-term use of the newer sedative-hypnotics may be a feasible and effective treatment option when used in conjunction with thorough medical assessment and regular patient follow-up. This review discusses these issues and discusses the pros and cons of long-term sedative-hypnotic use.
Collapse
Affiliation(s)
- Azmeh Shahid
- Department of Psychiatry, University of Toronto and Toronto Western Hospital, University Health Network, Toronto, Canada
| | | | | | | |
Collapse
|
21
|
|
22
|
Yarborough BJH, Janoff SL, Stevens VJ, Kohler D, Green CA. Delivering a lifestyle and weight loss intervention to individuals in real-world mental health settings: Lessons and opportunities. Transl Behav Med 2011; 1:406-415. [PMID: 22229048 PMCID: PMC3249757 DOI: 10.1007/s13142-011-0056-9] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
BACKGROUND: Most weight loss interventions for obesity-related risks exclude people with serious mental health conditions. PURPOSE: To adapt a successful lifestyle/weight loss intervention for this population, deliver it in an HMO and two public mental health clinics, and concurrently measure implementation factors. METHODS: Developmental and implementation-focused formative evaluations guided adaptations and identified barriers/facilitators to successful program deployment. RESULTS: Adaptations included content specific to the population's needs, consciousness-raising among clinicians and patients, additional case-management, and greater program flexibility. Barriers included instability in both settings from different sources. Facilitators included familiarity with groups, manual integrity, and appreciation of the program. It was delivered consistently across settings with maximum exposure and fairly good fidelity to the protocol (mean rating=1.7, 2.0=complete fidelity). CONCLUSIONS: This mixed-method implementation evaluation demonstrated that lifestyle/weight loss interventions in mental health settings are complex, but feasible, and valued by participants. Main program outcomes will be reported at the trial's conclusion.
Collapse
Affiliation(s)
| | - Shannon L Janoff
- />Center for Health Research, Kaiser Permanente Northwest, Portland, OR USA
| | - Victor J Stevens
- />Center for Health Research, Kaiser Permanente Northwest, Portland, OR USA
| | - David Kohler
- />Cascadia Behavioral Healthcare, Portland, OR USA
| | - Carla A Green
- />Center for Health Research, Kaiser Permanente Northwest, Portland, OR USA
| |
Collapse
|
23
|
Goldstein TR, Goldstein BI, Mantz MB, Bailey B, Douaihy A. A brief motivational intervention for preventing medication-associated weight gain among youth with bipolar disorder: treatment development and case report. J Child Adolesc Psychopharmacol 2011; 21:275-80. [PMID: 21663430 PMCID: PMC3111861 DOI: 10.1089/cap.2010.0104] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Bipolar disorder (BP) in youth is an impairing psychiatric disorder associated with high rates of relapse and recurrence. High rates of psychiatric and medical co-morbidities account for additional illness burden in pediatric BP. The elevated risk of overweight and obesity in this population is of particular concern. One of the likely etiologies for weight gain in youth with BP is use of mood-stabilizing medications. Although these medications can be effective for mood stabilization, excessive weight gain is a common side effect. Obesity is associated with a host of medical problems and is also correlated with worse psychiatric outcomes in BP, rendering the prevention of weight gain in this population particularly clinically relevant. In this article, we describe the rationale and development of a brief motivational intervention for preventing weight gain among youth with BP initiating mood-stabilizing pharmacological treatment and then present a case example illustrating the principles of the intervention.
Collapse
Affiliation(s)
- Tina R. Goldstein
- Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
| | - Benjamin I. Goldstein
- Department of Psychiatry, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada
| | - Michael B. Mantz
- University of California at Irvine School of Medicine, Irvine, California
| | - Bridget Bailey
- Department of Social Work, The Ohio State University, Columbus, Ohio
| | - Antoine Douaihy
- Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
| |
Collapse
|
24
|
Marques-Vidal P, Pécoud A, Hayoz D, Paccaud F, Mooser V, Waeber G, Vollenweider P. Normal weight obesity: relationship with lipids, glycaemic status, liver enzymes and inflammation. Nutr Metab Cardiovasc Dis 2010; 20:669-675. [PMID: 19748248 DOI: 10.1016/j.numecd.2009.06.001] [Citation(s) in RCA: 96] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/19/2008] [Revised: 03/24/2009] [Accepted: 06/02/2009] [Indexed: 02/06/2023]
Abstract
BACKGROUND AND AIMS Normal weight obesity (NWO) is defined as an excessive body fat associated with a normal body mass index (BMI) and has been associated with early inflammation, but its relationship with cardiovascular risk factors await investigation. METHODS AND RESULTS Cross-sectional study including 3213 women and 2912 men aged 35-75 years to assess the clinical characteristics of NWO in Lausanne, Switzerland. Body fat was assessed by bioimpedance. NWO was defined as a BMI<25 kg/m(2) and a % body fat ≥66(th) gender-specific percentiles. The prevalence of NWO was 5.4% in women and less than 3% in men, so the analysis was restricted to women. NWO women had a higher % of body fat than overweight women. After adjusting for age, smoking, educational level, physical activity and alcohol consumption, NWO women had higher blood pressure and lipid levels and a higher prevalence of dyslipidaemia (odds-ratio=1.90 [1.34-2.68]) and fasting hyperglycaemia (odds-ratio=1.63 [1.10-2.42]) than lean women, whereas no differences were found between NWO and overweight women. Conversely, no differences were found between NWO and lean women regarding levels of CRP, adiponectin and liver markers (alanine aminotransferase, aspartate aminotransferase and gamma glutamyl transferase). Using other definitions of NWO led to similar conclusions, albeit some differences were no longer significant. CONCLUSION NWO is almost nonexistent in men. Women with NWO present with higher cardiovascular risk factors than lean women, while no differences were found for liver or inflammatory markers. Specific screening of NWO might be necessary in order to implement cardiovascular prevention.
Collapse
|
25
|
Abstract
OBJECTIVE Using Wakefield's conceptualization of mental disorder as "harmful mental dysfunction" (Wakefield, Am Psychol, 47, 373-388, 1992), we examined the evidence for including obesity as a mental disorder in DSM-V. METHOD We searched computer databases and examined reference lists from review articles published in the last 10 years to identify empirical papers relevant to the present review. RESULTS Obesity is a condition of heterogeneous etiology that is harmful for most individuals. However, there is scant evidence that obesity, in general, is caused by mental dysfunction. Although recent work examining the neurocircuitry of energy balance has suggested that mental dysfunction may be involved in the etiology of specific obesity phenotypes, findings are too preliminary to support classification of obesity as a mental disorder. Nevertheless, there is evidence that obesity is related to mental disorder and many of the medications used to treat psychiatric illness. DISCUSSION There is little evidence for including obesity as a mental disorder in DSM-V. However, results confirm the importance of monitoring adiposity routinely among patients with psychiatric illness.
Collapse
Affiliation(s)
- Marsha D Marcus
- Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA.
| | | |
Collapse
|
26
|
Chen PH, Cheng SJ. Depression in Parkinson Disease: Current Understanding and Treatment. INT J GERONTOL 2008. [DOI: 10.1016/s1873-9598(09)70006-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
27
|
Abstract
A depressão é uma doença que pode levar a mudanças no peso, influenciadas por fatores específicos da doença, como alterações no apetite e na atividade física, ou pelos antidepressivos. Este artigo objetiva analisar os estudos que descrevem os efeitos dos antidepressivos em alterações do peso corporal. Realizou-se uma pesquisa nas bases de dados Medline, Lilacs e Cochrane, utilizando as palavras chaves " antidepressivo" e " peso" . Foram selecionados os estudos que analisaram o tema em pacientes depressivos, priorizando-se aqueles relacionados às drogas mais utilizadas nos serviços de saúde no Brasil. A análise dos estudos indicou que a mudança de peso atribuída ao tratamento com antidepressivos apresenta resultados ainda controversos, sendo influenciada por fatores como o tempo de uso e a dosagem do medicamento, estudos com poder limitado, entre outros. Assim, estudos com maior poder, tendo como foco a ação das drogas antidepressivas nas alterações do peso corporal em pacientes depressivos, ainda são necessários.
Collapse
|
28
|
Abstract
The aim of the present paper was to describe the mechanisms and management of antipsychotic-induced weight gain in schizophrenia patients. A comprehensive literature review of all available articles on the mechanisms and management of antipsychotic-induced weight gain was done by searching databases PsychINFO and PubMed. A summary of the available guidelines for monitoring of antipsychotic-induced weight gain and metabolic syndrome is also provided. There has been a substantial increase in the number of studies investigating the mechanisms and management of antipsychotic-induced weight gain after 2002. These include advances in the understanding of pharmacogenomics of weight gain and several randomized controlled trials (RCTs) evaluating pharmacological and psychological treatments to promote weight loss. The most effective strategy for prevention of weight gain is the choice of antipsychotic medication with low weight gain potential. In individuals with established weight gain and metabolic issues, switching to an antipsychotic agent with lower weight gain potential and/or lifestyle modifications with physical activity are most effective in promoting weight loss. Pharmacological agents such as orlistat and sibutramine are effective in general obesity but have not been sufficiently evaluated in antipsychotic-induced weight gain. The case to prescribe routine pharmacological treatment to promote weight loss is weak. Long-term, pragmatic studies are required to inform clinical practice. Weight gain in schizophrenia is associated with significant physical and psychological morbidity. Achieving an optimal trade-off between effectiveness and side-effects of antipsychotic agents, although difficult, is achievable. This should be based on three main principles: (i) a shared decision-making model between the patient, clinician and carer(s) when choosing an antipsychotic; (ii) a commitment to baseline and follow-up monitoring with explicit identification of the responsible individual or team; and (iii) the adoption of clear structured protocols for clinicians to follow in case of clinically significant weight gain and metabolic issues, which should incorporate greater collaboration between various health professionals from psychiatric and medical specialist services.
Collapse
Affiliation(s)
- Sanil Rege
- Northern Sydney Central Coast Mental Health Service, Wyong Psychiatric Emergency Care Centre, Wyong Hospital, NSW, Australia.
| |
Collapse
|
29
|
Kolotkin RL, Corey-Lisle PK, Crosby RD, Swanson JM, Tuomari AV, L'italien GJ, Mitchell JE. Impact of obesity on health-related quality of life in schizophrenia and bipolar disorder. Obesity (Silver Spring) 2008; 16:749-54. [PMID: 18239573 DOI: 10.1038/oby.2007.133] [Citation(s) in RCA: 75] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
OBJECTIVE Studies have reported that up to 60% of individuals with schizophrenia and 68% of those with bipolar disorder are overweight/obese. This paper explores the health-related quality of life (HRQOL) of individuals with schizophrenia or bipolar disorder as a function of obesity status. METHODS AND PROCEDURES Two hundred and eleven participants were recruited from four psychiatric programs (outpatient, day treatment, case management, and psychosocial rehabilitation). HRQOL was assessed using both a general measure (Medical Outcomes Study Short-Form-36 (SF-36)) and a weight-related measure (Impact of Weight on Quality of Life-Lite (IWQOL-Lite)). To interpret HRQOL scores obtained by the obese group, we compared scores to those obtained by reference groups from the weight-loss literature. RESULTS Sixty-three percent of participants with schizophrenia and 68% of those with bipolar disorder were obese. Obese participants were more likely to be women, on mood stabilizers, taking a greater number of psychiatric medications, and to have poorer weight-related and general HRQOL. Weight-related HRQOL in the obese psychiatric sample was more impaired than in outpatient and day treatment samples seeking weight loss but less impaired than in gastric-bypass patients. Several of the physical domains of general HRQOL were more impaired for the obese psychiatric sample than for the outpatient weight-loss sample. However, physical functioning was less impaired for the obese psychiatric sample than for gastric-bypass patients. DISCUSSION The presence of obesity among individuals with schizophrenia or bipolar disorder is associated with decreased HRQOL. These results have implications for prevention and management of weight gain in individuals with schizophrenia or bipolar disorder.
Collapse
|
30
|
Baumann M, Spitz E, Guillemin F, Ravaud JF, Choquet M, Falissard B, Chau N. Associations of social and material deprivation with tobacco, alcohol, and psychotropic drug use, and gender: a population-based study. Int J Health Geogr 2007; 6:50. [PMID: 17996098 PMCID: PMC2211297 DOI: 10.1186/1476-072x-6-50] [Citation(s) in RCA: 81] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2007] [Accepted: 11/09/2007] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND The aim was to assess the relationships between social and material deprivation and the use of tobacco, excessive alcohol and psychotropic drugs by both sexes and in various age groups. Greater knowledge concerning these issues may help public health policy-makers design more effective means of preventing substance abuse. METHODS The sample comprised 6,216 people aged > or 15 years randomly selected from the population in north-eastern France. Subjects completed a post-mailed questionnaire covering socio-demographic characteristics, occupation, employment, income, smoking habit, alcohol abuse and "psychotropic" drug intake (for headache, tiredness, nervousness, anxiety, insomnia). A deprivation score (D) was defined by the cumulative number of: low educational level, manual worker, unemployed, living alone, nationality other than western European, low income, and non-home-ownership. Data were analysed using adjusted odds ratios (ORa) computed with logistic models. RESULTS Deprivation was common: 37.4% of respondents fell into category D = 1, 21.2% into D = 2, and 10.0% into D > or 3a re men than women reported tobacco use (30.2% vs. 21.9%) and alcohol abuse (12.5% vs. 3.3%), whereas psychotropic drug use was more common among women (23.8% vs. 41.0%). Increasing levels of deprivation were associated with a greater likelihood of tobacco use (ORa vs. D = 0: 1.16 in D = 1, 1.49 in D = 2, and 1.93 in D > or = 3), alcohol abuse (1.19 in D = 1, 1.32 in D = 2, and 1.80 in D > or = 3) and frequent psychotropic drug intake (1.26 in D = 1, 1.51 in D = 2, and 1.91 in D > or = 3). These patterns were observed in working/other non-retired men and women (except for alcohol abuse in women). Among retired people, deprivation was associated with tobacco and psychotropic drug use only in men. CONCLUSION Preventive measures should be designed to improve work conditions, reduce deprivation, and help deprived populations to be more aware of risk and to find remedial measures.
Collapse
Affiliation(s)
- Michèle Baumann
- INtegrative research unit on Social and Individual DEvelopment (INSIDE), University of Luxembourg, Faculty LSHASE, Luxembourg; Luxembourg
| | | | - Francis Guillemin
- EA 4003, Ecole de Santé Publique, University Henri Poincaré – Nancy 1, Faculté de Médecine, Vandoeuvre-lès-Nancy, France
| | | | - Marie Choquet
- INSERM, U669, Paris, France
- Univ Paris-Sud, Paris, France
- Univ Paris-Descartes, UMR-S0669 Paris, France
| | - Bruno Falissard
- INSERM, U669, Paris, France
- Univ Paris-Sud, Paris, France
- Univ Paris-Descartes, UMR-S0669 Paris, France
- AP-HP, Villejuif, France
| | - Nearkasen Chau
- INSERM, U669, Paris, France
- Univ Paris-Sud, Paris, France
- Univ Paris-Descartes, UMR-S0669 Paris, France
| | | |
Collapse
|
31
|
Hellerstein DJ, Almeida G, Devlin MJ, Mendelsohn N, Helfand S, Dragatsi D, Miranda R, Kelso JR, Capitelli L. Assessing obesity and other related health problems of mentally ill Hispanic patients in an urban outpatient setting. Psychiatr Q 2007; 78:171-81. [PMID: 17417734 DOI: 10.1007/s11126-007-9038-y] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
OBJECTIVE This paper describes the role of an agency Clinical Director in developing a project to assess and begin to address obesity-related health problems of patients treated in a community-based mental health clinic in New York City. After a five year review of outpatient deaths revealed a high rate of deaths from cardiovascular and diabetes-related issues, the Clinical Director assembled a group of clinicians, researchers, and administrative staff to design a pilot project to assess health and nutrition status of primarily Hispanic day treatment patients with severe and persistent mental illness. METHOD About 69 of the 105 patients at the clinic were assessed by chart review, interview about nutritional habits and medical care, and somatic measurements for blood pressure, weight, girth, body mass index (BMI), glucose and lipid levels. RESULTS Patients were predominantly between the ages of 25 and 64 years, 51% were female, and 78% were Hispanic. Around 57% were diagnosed with schizophrenia-spectrum disorders, 86% were receiving antipsychotic medications, and 25% were on two or more antipsychotics. Only 11% of the women and 41% of the men had normal weight. A total of 29% of the women and 18% of the men were overweight (BMI = 25-29.9); and an additional 60% of the women and 41% of the men were obese (BMI > or = 30). Atypical antipsychotic treatment was significantly associated with obesity (BMI > or = 30) (chi sq = 5.5, df = 1, P < 0.025). Using American Heart Association criteria, waist measurements showed significant abdominal obesity among female patients. Blood pressure was elevated in 77% of the patients: 45% were pre-hypertensive with BP 120-139/80-89 and 32% were hypertensive with BP > or = 140/90. About 53% had elevated random blood glucoses (>110 mg/dl). On the positive side, patients generally had had recent medical follow-up, and most had adequate cooking facilities. CONCLUSIONS This project revealed that these predominantly Hispanic, severely mentally ill individuals were at high risk for cardiac illness, highlighting the need for developing culturally-sensitive interventions in urban outpatient psychiatric settings. Findings were disseminated in educational presentations and clinical discussions, and have mobilized an institutional effort to significantly improve medical monitoring for these patients.
Collapse
Affiliation(s)
- David J Hellerstein
- New York State Psychiatric Institute, Harkness Pavilion, 180 Fort Washington Ave., New York, NY 10032, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Melville CA, Hamilton S, Hankey CR, Miller S, Boyle S. The prevalence and determinants of obesity in adults with intellectual disabilities. Obes Rev 2007; 8:223-30. [PMID: 17444964 DOI: 10.1111/j.1467-789x.2006.00296.x] [Citation(s) in RCA: 114] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
People with intellectual disabilities experience significant health inequalities compared with the general population, including a shorter life expectancy and high levels of unmet health needs. Another accepted measure of health inequalities, the prevalence of obesity, has been shown to be higher in adults with intellectual disabilities than in the general population. While the factors contributing to the increased prevalence among adults with intellectual disabilities are not well understood, the high rates of obesity among younger adults highlight the need for further research involving children and adolescents with intellectual disabilities. To take forward the priorities for research and the development of effective, accessible services, there is a need for collaboration between professionals working in the fields of intellectual disabilities and obesity.
Collapse
Affiliation(s)
- C A Melville
- Section of Psychological Medicine, University of Glasgow, Glasgow, UK.
| | | | | | | | | |
Collapse
|
33
|
Gobshtis N, Ben-Shabat S, Fride E. Antidepressant-induced undesirable weight gain: Prevention with rimonabant without interference with behavioral effectiveness. Eur J Pharmacol 2007; 554:155-63. [PMID: 17116301 DOI: 10.1016/j.ejphar.2006.10.028] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2006] [Revised: 09/27/2006] [Accepted: 10/02/2006] [Indexed: 10/24/2022]
Abstract
Antidepressant pharmacotherapy has dramatically improved the quality of life for many patients. However, prolonged use may induce weight gain, resulting in enhanced risk for treatment noncompliance. Cannabinoid CB(1) receptor antagonists decrease food intake and body weight, but may also affect mood. We investigated in female Sabra mice first, whether acute treatment with the cannabinoid receptor antagonist rimonabant (5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide, SR141716, 5 mg/kg) interfered with the tricyclic antidepressant desipramine (15 mg/kg) or the selective serotonin reuptake inhibitor fluoxetine (20 mg/kg) in the Porsolt forced swimming test. Second, whether chronic treatment (3 months) with desipramine (5 mg/kg) enhanced weight gain and whether cotreatment with rimonabant (2 mg/kg), prevented the excessive weight gain, while retaining antidepressant effectiveness. Motor activity and anxiety-like behavior were also investigated. The acute studies indicated that rimonabant did not influence 'antidepressant' activity of desipramine or fluoxetine. In the chronic studies, desipramine enhanced weight gain, despite the observation that the injection procedure reduced weight gain. The enhanced weight gain continued at least 35 days after treatment ended. Rimonabant reduced weight gain to which no tolerance developed and which persisted at least 30 days beyond treatment. Mice cotreated with rimonabant and desipramine had body weights closer to controls or to those receiving rimonabant alone than to those treated with desipramine alone. The antidepressant effects of desipramine were maintained throughout treatment; this was not altered by the chronic rimonabant treatment at any time, although rimonabant together with desipramine transiently enhanced anxiety-like behavior. These observations suggest that combined treatment with antidepressants and cannabinoid CB(1) receptor antagonist to prevent undesirable weight gain, should be further investigated.
Collapse
Affiliation(s)
- Nikolai Gobshtis
- Department of Behavioral Sciences, College of Judea and Samaria, Ariel, Israel
| | | | | |
Collapse
|
34
|
Müller DJ, Kennedy JL. Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics 2006; 7:863-87. [PMID: 16981847 DOI: 10.2217/14622416.7.6.863] [Citation(s) in RCA: 111] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Classic and modern antipsychotics can induce substantial weight gain causing diabetes, lipid abnormalities and psychological distress. Treatment emergent weight gain varies within the broad class of antipsychotics; however, an individual's propensity to develop weight gain largely depends on genetic factors. The first part of this review highlights current ideas and concepts related to antipsychotic-induced weight gain, including principles on energy homeostasis. The second part summarizes genetic findings emphasizing studies published after 2003 as prior studies have been reviewed in detail elsewhere. Candidate gene studies have produced significant findings in the 5-hydroxytryptamin 2C (5HT2C) and adrenergic alpha2a (ADRalpha2a) receptor genes, as well as in the leptin, guanine nucleotide binding protein (GNB3) and synaptomal-associated protein 25kDa (SNAP25) genes. Results from genome-wide association and linkage studies point to several chromosomal regions (e.g., 12q24) and some specific genes (e.g., promelanin concentrating hormone [PMCH], polycyctic kidney and hepatic disease 1 [PKHD1], peptidylglycine alpha-amidating monooxygenase [PAM]). However, more efforts are needed before risk prediction and personalized medicine can be made available for antipsychotic-induced weight gain.
Collapse
Affiliation(s)
- Daniel J Müller
- Charité University Medicine Berlin, Department of Psychiatry, Campus Charité Mitte, St. Hedwig KlinikTurmstrasse 21, 10559 Berlin, Germany.
| | | |
Collapse
|
35
|
Abstract
The number of bariatric surgical procedures performed in the United States has increased steadily during the past decade. Currently accepted criteria for consideration of bariatric surgery include a body mass index (calculated as weight in kilograms divided by the square of height in meters) of 40 kg/m2 or greater (or >35 kg/m2 with obesity-related comorbidities), documented or high probability of failure of nonsurgical weight loss treatments, and assurance that the patient is well informed, motivated, and compliant. Appropriate patient selection is important in achieving optimal outcomes after bariatric surgery. In this article, we review our approach to the medical and psychological assessment of patients who want to undergo bariatric surgery. The medical evaluation is designed to identify and optimally treat medical comorbidities that may affect perioperative risks and long-term outcomes. The psychiatric and psychological assessment identifies factors that may influence long-term success in maintaining weight loss and prepares the patient for the lifestyle changes needed both before and after surgery.
Collapse
Affiliation(s)
- Maria L Collazo-Clavell
- Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
| | | | | | | |
Collapse
|
36
|
Kolotkin RL, Crosby RD, Corey-Lisle PK, Li H, Swanson JM. Performance of a weight-related measure of Quality of Life in a psychiatric sample. Qual Life Res 2006; 15:587-96. [PMID: 16688492 DOI: 10.1007/s11136-005-4627-4] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/28/2005] [Indexed: 12/27/2022]
Abstract
The Impact of Weight on Quality of Life-Lite (IWQOL-Lite) questionnaire has been validated previously in weight loss program participants and community volunteers. Because of the prevalence of obesity in individuals with schizophrenia and bipolar disorder, this study evaluates the psychometric performance of the IWQOL-Lite in these populations. A sample of 111 individuals with schizophrenia (mean age = 43.5; mean BMI = 32.6; 42.3% female; 59.5% Caucasian) and 100 with bipolar disorder (mean age = 42.8; mean BMI = 34.8; 66.0% female; 81.0% Caucasian) were recruited from four programs. Height and weight measurements were taken and participants completed the IWQOL-Lite, Medical Outcomes Study Short-Form-36 (SF-36), and Global Ratings of quality of life. Sixty-five participants completed the IWQOL-Lite 1-2 weeks later to determine stability of results. Sixty-four percent of schizophrenic participants and 68.0% of bipolar participants were obese. The IWQOL-Lite demonstrated excellent reliability in the current sample, with alpha coefficients ranging from 0.874 to 0.970 and test-retest coefficients ranging from 0.740 to 0.945. Correlations with collateral measures and BMI supported the construct validity of the IWQOL-Lite in this population. The IWQOL-Lite is a reliable and valid measure for assessing weight-related quality of life in individuals with schizophrenia and bipolar disorder.
Collapse
Affiliation(s)
- Ronette L Kolotkin
- Obesity and Quality of Life Consulting, 1004 Norwood Avenue, Durham, NC 27707, USA.
| | | | | | | | | |
Collapse
|
37
|
Klam J, McLay M, Grabke D. Personal Empowerment Program: Addressing Health Concerns in People with Schizophrenia. J Psychosoc Nurs Ment Health Serv 2006; 44:20-8. [PMID: 16937771 DOI: 10.3928/02793695-20060801-04] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Three staff nurses in the Outpatient Schizophrenia Service of the Foothills Medical Centre in Calgary, Alberta, Canada, became concerned about the weight gain of their patients. Patients and their family members were also concerned and asking for help. Before integrating a program to address these concerns, staff first had to demonstrate that a program of this nature would be beneficial for clinic patients. Of the 75 clients screened, many presented with problems in the areas of weight, blood pressure, and fasting blood sugar and lipid levels. Although not a research study, an 8-month pilot project was implemented to address these concerns. It was hypothesized that integrating all dimensions of wellness in patient programming would have a positive effect on various defined indicators (e.g., weight, body mass index, blood pressure, and fasting blood sugar and lipid levels). Screening tests before, during, and after the 8-month project provided the physical outcome measurements. Social and psychological outcomes were described through observation and group member feedback. The positive results are significant in terms of empowering patients in the long-term management of their health.
Collapse
Affiliation(s)
- Joan Klam
- Outpatient Schizophrenia Services, Foothills Medical Centre, Calgary, Alberta, Canada.
| | | | | |
Collapse
|
38
|
Strine TW, Chapman DP, Kobau R, Balluz L. Associations of self-reported anxiety symptoms with health-related quality of life and health behaviors. Soc Psychiatry Psychiatr Epidemiol 2005; 40:432-8. [PMID: 16003592 DOI: 10.1007/s00127-005-0914-1] [Citation(s) in RCA: 73] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 01/28/2005] [Indexed: 11/26/2022]
Abstract
BACKGROUND Anxiety disorders affect approximately 19 million American adults annually and have been associated with impaired health-related quality of life (HRQOL), an increased rate of adverse health behaviors, and poor outcomes related to chronic illness in studies conducted in clinical populations. Our study was designed to examine the association of self-reported anxiety symptoms with HRQOL and health behaviors among a representative sample of US community-dwellers. METHODS Data were obtained from the Behavioral Risk Factor Surveillance System,an ongoing, state-based, random-digit telephone survey of the noninstitutionalized US population aged > or = 18 years. In 2002, HRQOL measures were administered in 18 states and the District of Columbia. RESULTS An estimated 15% of persons reported frequent (> or = 14 days in the past 30 days) anxiety symptoms. After adjusting for frequent depressive symptoms and sociodemographic characteristics, those with frequent anxiety symptoms were significantly more likely than those without to report fair or poor general health (vs. excellent, very good, or good general health), frequent physical distress, frequent activity limitations, frequent sleep insufficiency, infrequent vitality, frequent mental distress, and frequent pain. In addition, they were more likely to smoke, to be obese, to be physically inactive, and to drink heavily. CONCLUSION Given their association with impaired HRQOL and adverse health behaviors, our results suggest that assessment of anxiety symptoms should be a facet of routine standard medical examinations.
Collapse
Affiliation(s)
- Tara W Strine
- Division of Adult and Community Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, 4770 Buford Highway NE, Mailstop K-66, Atlanta, GA 30341, USA.
| | | | | | | |
Collapse
|
39
|
Abstract
Individuals with psychiatric disorders tend to have excessive morbidity. They typically have high rates of respiratory illnesses, infectious diseases, substance abuse (including smoking), obesity, diabetes mellitus, and cardiovascular disease (CVD). Persons with schizophrenia and affective disorders also have a high prevalence of risk factors for CVD, such as diabetes and obesity, which are on the order of 1.5 to 2.0 times higher than in the general population; this translates into increased mortality rates due to CVD. The use of certain psychotropics results in metabolic sequelae, such as obesity, dyslipidemia, glucose dysregulation, and the metabolic syndrome. These sequelae exacerbate the already elevated risk of CVD and diabetes in this group of people. Therefore, the use of psychotropic agents that result in, for example, excessive weight gain not only add another complication for physicians managing a patient with schizophrenia but also may have serious prognostic and cost implications with respect to treatment-related diabetes and coronary disease incidence. The recent American Diabetes Association (ADA) Consensus Panel concluded that some agents are associated with greater diabetes risk than others. The current review describes the prevalence of the metabolic syndrome in people with affective disorders and schizophrenic populations, its prognostic relevance, and its exacerbation among patients treated with particular psychotropic agents, including certain atypical antipsychotics, selective serotonin reuptake inhibitors, and mood stabilizers. The costs associated with the treatment of the metabolic syndrome, diabetes, and coronary heart disease in populations with schizophrenia are also described.
Collapse
Affiliation(s)
- Daniel E Casey
- UHN 80 Department of Psychiatry, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, Oregon 97239, USA.
| |
Collapse
|